Clinical Trial Update: To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous cipargamin in severe malaria has completed and posted results, detailing efficacy, safety, tolerability and pharmacokinetic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Cipargamin (cipargamin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Severe Malaria | Phase 2 | Status: COMPLETED | Results posted: 2026-04-09